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Abstract
Dupuytren’s contracture (DC) is a benign fibro-proliferative disease of the hand causing fibrotic nodules and fascial
Q2
cords which determine debilitating contracture and deformities of fingers and hands. The present study was
designed to characterize pro-inflammatory cytokines and growth factors involved in the pathogenesis, progression
and recurrence of this disease, in order to find novel targets for alternative therapies and strategies in controlling
DC. The expression of pro-inflammatory cytokines and of growth factors was detected by immunohistochemistry in
fibrotic nodules and normal palmar fascia resected respectively from patients affected by DC and Carpal Tunnel
Syndrome (CTS; as negative controls). Reverse transcription (RT)-PCR analysis and immunofluorescence were
performed to quantify the expression of transforming growth factor (TGF)-β1, interleukin (IL)-1β and vascular
endothelial growth factor (VEGF) by primary cultures of myofibroblasts and fibroblasts isolated from Dupuytren’s
nodules. Histological analysis showed high cellularity and high proliferation rate in Dupuytren’s tissue, together to
the presence of myofibroblastic isotypes; immunohistochemical staining for macrophages was completely negative.
In addition, a strong expression of TGF-β1, IL-1β and VEGF was evident in the extracellular matrix and in the
cytoplasm of fibroblasts and myofibroblasts in Dupuytren’s nodular tissues, as compared with control tissues.
These results were confirmed by RT-PCR and by immunofluorescence in pathological and normal primary cell
cultures. These preliminary observations suggest that TGF-β1, IL-1β and VEGF may be considered potential
therapeutic targets in the treatment of Dupuytren’s disease (DD).
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INTRODUCTION
Dupuytren’s disease (DD) has been defined as a benign progress-
Q3
Q4
ive proliferative fibroplasia of the fascia palmaris of the hand,
which results in contracture of the fingers and subsequent reduc-
Abbreviations: CTS, Carpal Tunnel Syndrome; DC, Dupuytren’s contracture; DD, Dupuytren’s disease; DMEM, Dulbecco’s essential medium; GAPDH, glyceraldehyde 3 phosphate
dehydrogenase; IL, interleukin; PCNA, proliferating cell nuclear antigen; RT, reverse transcription; TGF, transforming growth factor; VEGF, vascular endothelial growth factor
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tion in the movement and inability to extend them [1]. The patho-
genesis of DD still remains unclear; the stages of the fibrotic
disease are classified as proliferative, involutional and resid-
ual on the basis of the histological appearance of the affected
fascia palmaris [2]. The proliferative phase is characterized by
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proliferation and differentiation of fibroblasts into myofibroblasts
under the influence of several different factors, causing forma-
tion of the nodules [3,4]. In the second phase, the involutional
stage, myofibroblasts proliferate and align along the long axis of
surrounding collagens bundles thus giving way to the formation
of fibrotic cords [5]. Finally, in the residual phase, the myofibro-
blasts are replaced by fibrocytes that progressively decrease in
number causing the formation of the avascular collagen cord [2].
Myofibroblasts seem to play a central role in the pathogenesis
of the fibrotic disease. These cells appear to be an intermedi-
ate phenotype between fibroblasts and smooth muscle cells and
generate the forces responsible for palmar fascia contracture [6].
Myofibroblasts are responsible for matrix deposition and con-
sequent contraction in DD. Many growth factors and cytokines
seem to be implicated in the aetiology of Dupuytren’s contrac-
ture (DC), among all transforming growth factor β1 (TGF-β1)
has been suggested to play a predominant role [7]. TGF-β1 is
responsible for the up-regulation of collagens and also of other
extracellular matrix components, all fundamental for connective
tissue remodelling [8]. TGF-β1 transduces a signal through an
heteromeric complex for formation of related type I and type II
transmembrane serine/threonine kinase receptors [9]; the signal
of the activated type I receptor induces SMAD signalling cascade
and the heteromeric SMAD complexes (SMAD2/3–SMAD4) ac-
cumulated in the nucleus regulate the expression of a large array
of target genes involved in myofibroblast proliferation, differenti-
ation and extracellular matrix synthesis [10–11]. Several studies
have identified pro-inflammatory cytokines in Dupuytren’s tis-
sues, but the molecular mechanisms by which inflammatory me-
diators activate myofibroblast differentiation are still unknown
[12]. Interleukin (IL)-6 was described as being involved in the
modulation of TGF-β1 and its receptor TGF-βRII, inducing then
fibroblasts proliferation [13]. TNF-α is another central mediator
of the fibrotic process, similar to TGF-β1 [14]: it has been iden-
tified as a mediator involved in the differentiation of fibroblasts
into myofibroblasts in the palm of patients affected by DD, via
activation of Wnt signalling pathway [15]. TNF-α may directly
regulate TGF-β1 expression, as shown in lung fibroblasts [16].
Yet, hypoxia and subsequent angiogenesis seem to play a role
in the pathophysiology of this disease [17]. Angiogenesis is in-
duced by several growth factors, but the most important molecule
is vascular endothelial growth factor (VEGF), also known as vas-
cular permeability factor [18]. Hypoxia activates the transcription
of hypoxia-inducible factor 1α (HIF-1α), which itself positively
regulates VEGF synthesis [19]. All these findings prompted us
to investigate the structural alterations of the fibromatous palmar
fascia in patients affected by DC and to analyse expression and
localization of the previously described growth factors in surgical
samples of palmar aponeurosis. In parallel, immunofluorescence
and reverse transcription (RT)-PCR analysis were conducted on
primary cultures of fibroblasts and myofibroblasts explanted from
Dupuytren’s nodules in the proliferative or involutional phases.
MATERIALS AND METHODS
Tissue samples were obtained from 26 patients (22 males and
four females, mean age 58 years, mean duration of clinical his-
tory 2.5 years) undergoing surgical dermo-fasciectomy for DC
(n= 18) and Carpal Tunnel Syndrome (CTS, n= 8, as negat-
ive controls). Pathological tissues were sampled from areas of
Dupuytren’s nodules (four specimens for each nodule). Control
samples (two specimens for each tissue fragment), characterized
by normal palmar fascia tissues, were collected from patients
undergoing hand surgery for CTS.
During excision, apart from anaesthesia, no other chemical
products or pharmaceutical drugs have been administered. All
samples were collected with the informed consent of the pa-
tient and the study protocol conformed to the ethical guidelines
of the 1975 Declaration of Helsinki. Experiments were per-
formed in compliance with the Italian laws and guidelines
concerning the patients’ written informed consent. The Eth-
ics Committee of the Policlinico Umberto I Hospital ap-
proved our study according to European Community and Italian
laws.
Samples (72 from DD and 16 from control patients) were fixed
in formalin and embedded in paraffin to be processed for histo-
logical staining and immunohistochemistry. The sections were
subjected to Haematoxylin and Eosin and Masson’s Trichrome
staining. In parallel, other tissue samples were used to obtain
primary cultures of pathological and normal fibroblasts.
IMMUNOHISTOCHEMISTRY
The immunohistochemical analysis was conducted using the
ABC/HRP technique (avidin complexed with biotinylated perox-
idase) on 4 μm thick paraffin sections that were cut using a rotat-
ive microtome. These sections were deparaffinized and hydrated
through decreasing ethanol series to distilled water, then subjec-
ted to microwave irradiation and immersed in citrate buffer (pH =
6) twice for 5 min each time. Subsequently, endogenous perox-
idase activity was quenched using 0.3 % hydrogenous peroxide
in methanol for 30 min. To evaluate the immunolocalization of
pro-inflammatory factors, VEGF, marker of myofibroblasts and
proliferating cell nuclear antigen (PCNA), the following anti-
bodies were employed: mouse anti-αSMA monoclonal antibody
(Leica; 1:100); rabbit anti-TGF-β1 polyclonal antibody (Santa
Cruz; 1:200); rabbit anti-IL1β polyclonal antibody (Santa Cruz;
1:100); rabbit anti-IL6 polyclonal antibody (Santa Cruz; 1:50);
mouse anti-VEGF monoclonal antibody (Santa Cruz; 1:100);
mouse anti-TNF-α monoclonal antibody (Santa Cruz; 1:200);
mouse anti-ICAM-1 monoclonal antibody (Santa Cruz; 1:25) and
mouse anti-PCNA monoclonal antibody (Santa Cruz; 1:100).
Incubation with the primary antibodies was performed
overnight at 4oC. Optimal antibody dilution and incubation times
were assessed in preliminary experiments. As negative con-
trol, the primary antibodies were omitted. After exposure to the
primary antibodies, all slides were rinsed twice in phosphate
buffer (pH = 7.4) and incubated for 1 h with the appropriate sec-
ondary biotinylated antibody at the final dilution of 1:200. The
secondary biotinylated antibodies against rabbit and mouse im-
munoglobulins were purchased from Abcam (biotinylated goat
anti-mouse antibody and biotinylated goat anti-rabbit antibody).
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The slides were then incubated with peroxidase-conjugated
avidin (Vector laboratories, Vectastain Elite ABC kit Stand-
ard*PK 6-100) for 30 min. Slides were washed in phosphate
buffer (pH = 7.4) and treated with 0.05 % 3,3-diaminobenzidine
(DAB) and 0.1 % H2O2. Finally, sections were counterstained
with Mayer’s haematoxylin and dehydrated rapidly. The staining
assessment was made by three experts. The intensity of the im-
mune reaction was assessed microdensitometrically using an IAS
2000 image analyser (Delta Sistemi) connected via a TV cam-
era to the microscope. Twelve 100 μm2 areas were delineated
in each section by measuring the diaphragm. The system was
calibrated taking the background obtained in sections exposed
to non-immune serum as zero. Quantitative data of the intensity
of immune staining were analysed statistically by ANOVA fol-
lowed by Duncan’s multiple range test as a post-hoc test. The
comparison of the expression levels of each antigen between the
palmar fascia from DD and CTS patients was carried out by Stu-
dent’s ttest. Statistical analysis was performed using the Graph-
Pad Prism. The results were considered statistically significant
with P< 0.05.
CELLS CULTURE
Dupuytren’s nodule tissues and normal palmar fascia tissues from
CTS patients were obtained by surgery. All samples were minced
using a sterile technique and placed in sterile 30-mm single-
well culture dishes. The wells were then flooded with 2 ml of
Dulbecco’s essential medium (DMEM) containing 4 % penicil-
lin/streptomycin (PS, Gibco) and 10 % FBS (Gibco). The media
was renewed three times weekly. Cells were observed adher-
ing to the bottom of the wells and were allowed to grow to
confluence. The cells were lifted from the wells using Tryp-
sin/EDTA, pelleted, washed and re-suspended in DMEM with
10 % FBS and 4 % penicillin/streptomycin. Four cell strains
were used in these experiments (four from DD patients and
four from control patients) and sub-cultured by less than 10
passages.
These primary cultures of pathological and normal cells were
used for establishing protein and mRNA expression of specific
pro-inflammatory factors and VEGF by immunofluorescence and
RT-PCR.
IMMUNOFLUORESCENCE
For immunofluorescence fibroblast primary cultures were grown
directly on Labteck chamber slides (Nunc) for at least 24 h, the
cells were then washed with PBS with Ca/Mg and fixed with 4 %
buffered paraformaldehyde for 20 min at 4 ◦C. Fixed cells were
incubated overnight at 4 ◦C with the primary antibody for α-
SMA, TGFβ1, IL1β, IL6, TNF-α and VEGF. After three washes
in 0.1 % Tween in PBS for 10 min each, the cells were incub-
ated with the secondary antibody, anti-mouse-fluorescein anti-
body (Abcam; 1:200) or anti-rabbit– rhodamine antibody (Ab-
cam; 1:200) for 2 h at room temperature. The nuclei were stained
with DAPI (Vectashield Mounting Medium with DAPI, Vector
Laboratories). The immunofluorescence was examined by con-
focal laser microscope (Nikon TE2000). Student’s ttest was used
to evaluate in the expression of each analysed antigen in DD and
control cells. The data were considered statistically significant
with P< 0.05.
RT-PCR
Cultured cells were suspended in TRIzol reagent (Invitrogen
Corporation) and total RNA was isolated using RNeasy Mi-
cro Kit (Qiagen). Real time PCR was conducted to determ-
ine the differences in mRNA expression levels of TGF-β1, IL-
1β and VEGF between normal and pathological fibroblasts in
culture.
The purity of the RNA was assessed using a UV/visible
spectophotomer (SmartSpec 3000, Bio-Rad Laboratories). One
microgram of total RNA was reverse transcribed using a high
capacity cDNA RT kit (Applied Byosystems) according to the
manufacturer’s instructions. RNA samples, RT buffer, dNTP mix,
RT random primers, multiscribe reverse transcriptase, RNase in-
hibitor and DEPC-treated distilled water were added in RNase-
free tubes on ice at the final volume of 20 μl. The thermal
cycler was programmed as follows: 25oC for 10 min, 37oC for
120 min and the reaction was stopped at 85oC for 5 min. For the
RNA reactions we used the follow primer pairs (Bio Basic In):
for TGF-β1 primer forward 5’-GCTGGACAGGAAGCTGGG-
3′ and primer reverse 5’-GGACACAACACGAGCAGAGA-3’,
for IL-1β primer forward 5’-GCTTCTGGTGATTCCCGCAA-
3’ and primer reverse 5’- GGGCTGTGAGAGTTCTTGGG-3’,
for VEGF primer forward 5’-AACCCCTAGGCCAGGTTGTA-
3’ and primer reverse 5’-CGGGATATGGAAGGGAAGCC-3′.
For glyceraldehyde 3 phosphate dehydrogenase (GAPDH), we
used primer forward 5’-GAGCAGTCCGGTGTCACTAC-3’ and
primer reverse 5’-TAGTAGCCGGGCCCTACTTT-3’. The spe-
cificity of the primers was verified by searching in the NCBI
database for any possible homologies to the cDNA of unrelated
proteins. Each PCR tube contained the following reagents at the
final volume of 50 μl: 0.2 μM of forward and reverse primers,
1 μg of template cDNA, 0.2 mM dNTP mix, 2.5 units of RedTaq
Genomic DNA polymerase (Sigma–Aldrich), MgCl2 and reac-
tion buffer 1×. The amplification was begun with an initial de-
naturation step at 94 ◦C (2 min) and was followed by 35 cycles,
each consisting of denaturation (30 s) at 94 ◦C, annealing (30 s)
at the appropriate temperature for each primer pair and extension
at 72 ◦C (1 min). Using the comparative critical cycle methods,
the expression levels of the target genes were normalized to the
GAPDH endogenous control. Data were analysed using the 7900
HT SDS software version 2.1 provided by applied Biosystems.
Statistical analysis was performed using Student’s ttest
(GraphPad Prism). The results were considered statistically sig-
nificant when the P< 0.05.
On the basis of these experiments we observed that TGF-β1
mRNA expression was the most significant among the examined
molecules, so we performed real time PCR on paraffinized tissue
in order to confirm mRNA expression data obtained from cell
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Figure 1 Immunohistochemical analysis of PCNA, CD68 and α-SMA markers in Dupuytren’s nodules and control tissues
The photomicrographs of Dupuytren’s nodular tissues showed an increasing number of PCNA (A) and αSMA-positive cells (C)
COLOUR
compared with the control tissues in which these markers resulted completely negative (D and F). Immunohistochemistry
for CD68 showed that the macrophages and monocytes were completely absent from the pathological nodule (B) similarly
to the normal tissue (E). (Magnification 40×).
cultures. For this last procedure, we used the same number of
specimens as before (four from DD patients and four from control
patients). Real time PCR was performed with the same protocol
employed in previously described PCR.
RESULTS
The rate of cell proliferation was first evaluated in Dupuytren’s
tissues by analysing the cellular proliferation marker known as
PCNA. Fibroblasts and myofibroblasts of Dupuytren’s nodules
had a strong nuclear staining of PCNA (Figure 1A), in contrast
with the normal palmar fascia tissue, in which cell staining was
completely absent (Figure 1D). We quantified the number of pos-
itive cells on the total number of cells in 10 different areas for
each experimental group and we expressed the ratio between
PCNA-positive cells and total cells as percentages (Figure 2).
The incidence of PCNA-positive nuclei in the fibromatous nod-
ules (87.65 % +− 4.98 %) was significantly (P< 0.0001) higher
than that in the normal palmar fascia tissues (18.43 % +− 7.15 %).
Our data demonstrate that these pathological samples belong to
the same proliferative stage of the disease that causes thicken-
ing and contracture of the palmar fascia. CD68 immunostaining
was performed and it was completely negative in Dupuytren’s
nodules (Figure 1B) similarly to normal tissues (Figure 1E),
thus confirming the absence of macrophages and monocytes in
Figure 2 Cell proliferation index in Dupuytren’s nodules and nor-
mal fascia palmar tissues
PCNA proliferative index is represented as a percentage of PCNA–
positive nuclei on the total number of cells in Dupuytren’s nodules
(87.65 % +− 4.98) and normal fascia palmar tissues (18 % +− 7.15). The
bar graph indicates the mean percentage of PCNA positive cells +− S.D.
Statistical analysis is performed using Student’s ttest. *P< 0.05.
the proliferative phase of the disease. Spindle-shaped cells in
Dupuytren’s nodule resulted α-SMA-positive (Figure 1C), this
is a reliable marker of the myofibroblastic phenotype; α-SMA
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Figure 3 Immunohistochemical analysis of pro-inflammatory markers TGF-β1, IL-1β and IL-6 in Dupuytren’s nodules and
controls
TGF-β1 was strongly expressed in the extracellular matrix and cytoplasm of proliferative myofibroblasts and fibroblasts
COLOUR
in the pathological tissue (A). TGF-β1 was moderately present in the cytoplasm of fibroblasts scattered in the loose
connective tissue of normal fascia palmar (D). IL-1β was strongly positive in Dupuytren’s myofibroblasts, rich nodules
showing cytoplasmic localization (B). IL-1β was completely absent from the extracellular matrix and weakly present in
the vascular endothelium and fibroblasts of normal palmar fascia (E). IL-6 was moderately expressed in the extracellular
matrix and fibroblasts of Dupuytren’s tissues (C) similarly to the control tissue (F). (Magnification 40×).
staining was weak or absent from the control tissues (Figure 1F).
The α-SMA high expression in Dupuytren’s tissues confirmed
the trans-differentiation from fibroblasts to contractile myofibro-
blastic phenotype.
Then TGF-β1 was highly expressed in the extracellular matrix
and by fibroblasts and myofibroblasts of Dupuytren’s proliferat-
ive nodules (Figure 3A); at the same time, a weak expression of
TGF-β1 was evidenced in the fibroblasts and vascular endothelial
cells of normal tissues, whereas it was completely negative in the
extracellular matrix of normal palmar fascia (Figure 3D). IL-
1β was then evaluated, showing positive immunoreaction in the
cytoplasm of fibroblasts and myofibroblasts, extracellular matrix
and vascular endothelial cells of the fibro-proliferative nodules
(Figure 3B). This pro-inflammatory cytokine was completely ab-
sent from the extracellular matrix of control samples, but weakly
present in the cytoplasm of capillary endothelial cells and fibro-
blasts (Figure 3E).
Il-6 was strongly expressed in the extracellular matrix in
its soluble form and moderately present in the proliferat-
ive myofibroblasts and fibroblasts of the Dupuytren’s nodules
(Figure 3C). In the controls, IL-6 was completely absent at level
of the loose connective tissue but moderately expressed in the
vascular endothelial cells and in the fibroblasts (Figure 3F), con-
firming that this cytokine is involved in the inflammatory process
that activate the fibrotic process of DD.
TNF-α was then analysed and it resulted moderately positive
in the extracellular matrix, fibroblasts and vascular endothelial
cells of the Dupuytren’s proliferative site (Figure 4A) similarly
to the control tissue (Figure 4C).
Finally, VEGF was strongly positive in vascular endothe-
lium, fibroblasts and myofibroblasts of Dupuytren’s nodules (Fig-
ure 4B); differently, VEGF was completely absent from the con-
trol tissues (Figure 4D).
All these data were supported by immunofluorescence of the
cultured fibroblasts and myofibroblasts isolated from Dupuytren’s
nodules, in which α-SMA was expressed by 50 % of the cells,
with uniform cytoplasmic distribution (Figure 5A), confirming
the presence of myofibroblasts; whereas α-SMA was completely
absent from the cells isolated from normal palmar fascia (Fig-
ure 5E). Pathological cultured fibroblasts and myofibroblasts were
also strongly positive for TGF-β1 expression, as compared with
normal fibroblasts, showing a granular cytoplasmic distribution
(Figures 5 B–F). Also, IL-1β was strongly present in Dupuytren’s
cell cultures (Figure 5C), but weakly present in normal fibroblasts.
Finally, IL-6 was weak and moderately present in pathological
(Figure 5D) and normal (Figure 5H) cultured cells.
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Figure 4 Immunohistochemical analysis of TNF-α and VEGF in Dupuytren’s nodules and control tissues
A moderate expression of TNF-α is seen in the extracellular matrix and fibroblasts of Dupuytren’s nodules (A) and
COLOUR
control tissues (C) (magnification 40×). VEGF immunoreactivity appears to be strongly positive in the extracellular matrix,
fibroblasts and myofibroblasts of Dupuytren’s nodules (B) (magnification 40×) compared with controls in which the staining
was completely absent from the amorphous substance and weakly expressed in the cytoplasm of normal fibroblasts (D)
(magnification 20×).
Figure 5 Immunofluorescence for αSMA and pro-inflammatory factors TGF-β1, IL-β, IL-6 in fibroblast cultures isolated
from Dupuytren’s nodules and normal palmar fascia
The pathological fibroblasts isolated from Dupuytren’s nodules (A) showed a strong expression of αSMA demonstrating
COLOUR
that 50 % of fibroblasts differ in myofibroblasts. In the normal fibroblasts, αSMA expression was completely absent (E).
TGF-β1 and IL-β were strongly expressed in the pathological fibroblasts isolated from Dupuytren’s tissues (B and C)
compared with the normal fibroblasts (F and G) that showed a weak expression of these pro-inflammatory factors. IL-6
was moderately expressed in the cytoplasm of pathological (D) and normal fibroblasts (H) (magnification 20×).
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Figure 6 Immunofluorescence for TNF-α and VEGF in fibroblast cells isolated from Dupuytren’s nodules and normal
palmar fascia
TNF-α was moderately expressed in the pathological fibroblast cultures (A) similarly to the control fibroblasts (C). A strong
COLOUR
VEGF expression was found in the cytoplasm of Dupuytren’s fibroblasts (B) differently from fibroblasts isolated from normal
palmar fascia in which this factor was completely absent (D). (Magnification 20×).
TNF-α was moderately expressed by pathological cells (Fig-
ure 6A), similarly to control fibroblasts (Figure 6C). VEGF was
found to be strongly expressed in the cytoplasm of fibroblasts
and myofibroblasts isolated from Dupuytren’s tissue (Figure 6B),
whereas was totally absent from normal fibroblasts (Figure 6D).
Our study confirmed that there was no difference in the in-
tensity of the expression of this pro-inflammatory cytokine and in
the percentage of TNF-α-positive cells between control cells and
pathological fibroblasts (Figure 7). The difference in the number
of IL-6-positive cells between the pathological and the normal
cell lines of fibroblasts was significant for P< 0.05 (Figure 7).
On the basis of the immunohistochemical and immunofluor-
escence results that showed a stronger expression of TGF-β1,
IL-1β and VEGF in pathological tissue, respect to normal tis-
sues, we then quantified their differences in mRNA expression
between normal and pathological tissues by RT-PCR (Figure 8).
An up-regulation of TGF-β1 (2.30 +− 0.05), IL-1β (2.02 +− 0.07)
and VEGF (1.97 +− 0.04) was demonstrated in fibroblasts from
Dupuytren’s nodules compared with normal fibroblasts (Fig-
ure 8A). RT-PCR data were demonstrated either on cultured cells
or in de-paraffinized tissue samples with P< 0.05.
DISCUSSION
DD is a condition in which the formation of nodules in the palm
of the hand precedes an eventual contracture of the fingers due to
fibrosis [20]. Clusters of macrophages and T-lymphocytes have
been observed, in addition to myofibroblasts, in the pathological
tissue [6,21–24]. Several growth factors and inflammatory cy-
tokines have been reported in the literature as molecules probably
Figure 7 Pro-inflammatory cytokines and VEGF positive cell index
in the fibroblasts isolated from Dupuytren’s nodules and normal
palmar fascia tissue
The bar graph indicates the mean percentage growth factors-posit-
ive cells +− S.D. Statistical analysis is performed using Student’s ttest.
*P< 0.0001 or **P< 0.05.
involved in the modulation of the pathogenesis of DD [25–27].
TGF-β1 is undoubtedly one of the cytokines most closely in-
volved in the process of fibrosis and is present at high amounts
in sites of chronic inflammation [28–32]. Moreover, some stud-
ies have also demonstrated in vitro that cultured Dupuytren’s
cells produce TGF-β1 and that TGF-β1 stimulates the growth
of Dupuytren’s fibroblasts [33]. As demonstrated by Kulkarni
and Karlsson [34], TGF-β1 plays other important roles in the
modulation of fibrosis and inflammation. Our data confirm that
TGF-β1 is more strongly present in DD extracellular matrix and
cells, than in the correspondent normal tissue and cells. A new
finding, not described in the previous available literature on this
topic, is the presence of a cytoplasmic granular fluorescent stain-
ing for TGF-β1, whose characteristic appearance represents an
interesting typical finding observed in DD myofibroblasts.
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Figure 8 Quantitative PCR analysis in Dupuytren’s nodules-
derived cells, in control tissue and in paraffinized tissue samples
(A, upper) PCR analysis of mRNA expression for TGF-β1, IL-1β and
VEGFa in nodules-derived cells and in control normal tissue. Data are
presented as mean +− S.E.M. Statistical analysis is performed using
Student’s ttest. *P< 0.05. (B, down) PCR analysis of mRNA expression
for TGF-β1 in paraffinized tissue samples from DD patients and control
ones.
A study performed by Iqbal et al. [35] confirmed the import-
ance of myofibroblasts in the pathogenesis of DD and also intro-
duced the possibility of alternative sources of DD myofibroblasts
originating from skin overlying nodule (SON) and perinodular fat
(PNF). Verjee et al. [15] have recently identified another possible
therapeutic target in the TNF, whose role may be hopefully rel-
evant in the better future knowledge of pathogenesis and therapy
of DD.
Nowadays, there are different therapeutic options for the treat-
ment of DD [36], but the real question still remains: what is the
primary cause in its pathogenesis? An important recent study [37]
postulates diverse origins of the myofibroblasts responsible for
kidney fibrosis. Notwithstanding the differences in comparison
with DD a possible general ‘common control’ of the mechanisms
of fibrosis may be activated even in different areas of the body
in response to appropriate stimuli. This ‘common control’ has to
be elucidated in further studies, but it probably constitutes the
central problem in DD and in other fibrosis-related pathologies.
Some authors emphasized on the possible role of Wnt sig-
nalling [38] in the pathogenesis of DD, but the present study
implicates even nine different loci involved in genetic suscept-
ibility to DD. The fact that six of these nine loci harbour genes
encoding proteins in the Wnt-signalling pathway suggests that
aberrations in this pathway may be the key to the process of
fibromatosis in DD. However further genome studies should be
performed in order to elucidate this interesting hypothesis.
Our results demonstrated that TGF-β1, IL-1β and VEGF are
markedly expressed in Dupuytren’s tissue and cultured myofibro-
blasts. This finding led us to postulate a pivotal role for these
molecules in the development of DC. The obtained informations
may provide a basis for the research of non-surgical treatment
regimens to reduce the recurrence and the progression of this
disease, ultimately attenuating hospitalization and post-surgical
rehabilitation for patients.
CLINICAL PERSPECTIVES
 The present study was designed to characterize pro-
inflammatory cytokines and growth factors involved in the
pathogenesis, progression and recurrence of DC, in order to
find novel targets for alternative therapies and strategies in
controlling DC. The pathogenesis of DC still remains un-
clear. Myofibroblasts are responsible for matrix deposition and
consequent contraction in DD. Many growth factors and cy-
tokines seem to be implicated in the aetiology of DC, among
all TGF-β has been suggested to play a predominant role.
TGF-β is responsible for the up-regulation of collagens and
also of other extracellular matrix components, all fundamental
for connective tissue remodelling. Therefore, we have invest-
igated the expression of pro-inflammatory cytokines and of
growth factors in fibrotic nodules and normal palmar fascia
resected respectively from patients affected by DC and CTS
(as negative controls).
 Histological analysis showed high cellularity and high prolif-
eration rate in Dupuytren’s tissue, together to the presence of
myofibroblastic isotypes. In addition, a strong expression of
TGF-β1, IL-1β and VEGFa was evident in the extracellular
matrix and in the cytoplasm of fibroblasts and myofibroblasts
in Dupuytren’s nodular tissues, as compared with control tis-
sues. These results were confirmed by RT-PCR and by im-
munofluorescence in pathological and normal primary cell
cultures. Pathological cultured fibroblasts and myofibroblasts
were strongly positive for TGF-β1 expression, as compared
with normal fibroblasts, showing a granular cytoplasmic dis-
tribution. Also IL-1β was strongly present in Dupuytren’s cell
cultures, but weakly present in normal fibroblasts. Finally, IL-
6 was weak and moderately present in pathological and normal
cultured cells.
 Our results demonstrated that TGF-β, IL-1β and VEGFa are
markedly expressed in Dupuytren’s tissue and cultured my-
ofibroblasts. This finding led us to postulate a pivotal role for
these molecules in the development of DC. The obtained in-
formations may provide a basis for the research of non-surgical
treatment regimens to reduce the recurrence and the progres-
sion of this disease, ultimately attenuating hospitalization and
post-surgical rehabilitation for patients. Therefore TGF-β1,
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IL-1β and VEGFa may be considered as potential therapeutic
targets in the treatment of DD.
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